> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# RA Capital Takes 5.1% Of Alector, Holding 7.5 Million Shares After Stock Offering
- URL: https://www.bullished.co/ra-capital-takes-5-1-of-alector-holding-7-5-million-shares-after-stock-offering-34840dda/
- Published: 2026-10-26T20:41:05.000Z
- Updated: 2026-11-05T20:14:10.000Z
- Description: The biotech investor says in a passive ownership filing it holds the stake with no aim of changing or influencing control of Alector.
- Author: Matteo Parrino
- Tags: SEC Filings, ALEC, Industry: Healthcare

RA Capital Management and its healthcare fund hold [7.5 million shares](https://www.sec.gov/Archives/edgar/data/0001346824/000134682426000247/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) of [Alector](https://www.bullished.co/tag/alec/), or 5.1% of the company, according to a passive ownership disclosure (Schedule 13G) filed Monday. The event date is October 19, the day Alector's public equity offering closed.

## Who holds the shares

The shares sit directly with RA Capital Healthcare Fund, L.P. The fund has handed sole power to vote and dispose of its holdings to RA Capital Management, its investment adviser.

Peter Kolchinsky and Rajeev Shah, the controlling persons of RA Capital's general partner, are co-filers. Each is shown with shared voting power over all 7,500,000 shares and none with sole power. The four filers expressly disclaim status as a group.

They certified that the shares were not acquired and are not held to change or influence control of Alector.

## How the 5.1% is calculated

The percentage rests on 111,656,919 shares outstanding as of July 31, 2026, as reported in Alector's quarterly report, plus 36,600,000 shares issued in the public offering that closed October 19, 2026, per an 8-K filed October 16.

Because 13G filers are passive holders, the form signals no plan to seek influence over the company, per the filers' own certification.

## A clinical-stage Alzheimer's developer

Alector is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. It has no products on the market, according to its annual report.

Its lead candidate, nivisnebart, is an antibody meant to raise levels of the protein progranulin in the brain. GSK is co-developing it, and a Phase 2 trial in early Alzheimer's enrolled about 282 patients. Alector has received $700 million in upfront payments under the GSK agreement and may receive milestone payments.

Its own preclinical programs include antibody, enzyme and siRNA candidates, many using its Alector Brain Carrier technology, designed to move drugs across the blood-brain barrier. Alector's market value was $204 million in Monday trading.

The filing is dated Monday under a joint filing agreement among the four RA Capital filers, covering the 7.5 million shares from the October 19 offering close.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — RA Capital Management, L.P. re: Alector, Inc. (ALEC)](https://www.sec.gov/Archives/edgar/data/0001346824/000134682426000247/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13G Exhibit 99.1 — JOINT FILING AGREEMENT](https://www.sec.gov/Archives/edgar/data/1346824/000134682426000247/ex-99-10262026%5F081005.htm?ref=bullished.co) — SEC EDGAR

### More on Alector

- [Deep Track Capital Reports 8.61% Passive Stake In Alector](https://www.bullished.co/deep-track-capital-reports-8-61-passive-stake-in-alector-91533e69/)
- [Alector Prices 36.6 Million Shares At $2.05, Adding 24.7% To Its Share Count](https://www.bullished.co/alector-prices-36-6-million-shares-at-2-05-adding-24-7-to-its-share-count-c18352d8/)
- [Alector Prices Stock Sale At $2.05 A Share, Aiming For $75.03 Million In Gross Proceeds](https://www.bullished.co/alector-prices-stock-sale-at-2-05-a-share-aiming-for-75-03-million-in-gross-proceeds-8f6be697/)

[All Alector (ALEC) coverage →](https://www.bullished.co/tag/alec/)